Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PTPRC | P08575 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982695 | 0.86 | SYK (0.46) | SYKALDH1A1MAPK1L3MBTL1GAA | |
| SCHEMBL29628910 | 0.85 | PTPRC (0.53) | SYKALDH1A1MAPK1L3MBTL1GAA | |
| SCHEMBL21102048 | 0.85 | PTPRC (0.53) | SYKALDH1A1MAPK1L3MBTL1GAA | |
| SCHEMBL24106783 | 0.84 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1GAANPC1RAB9A | |
| SCHEMBL11499533 | 0.84 | SYK (0.53) | SYKALDH1A1MAPK1L3MBTL1GAA | |
| SCHEMBL21471580 | 0.84 | PTPRC (0.47) | SYKALDH1A1MAPK1L3MBTL1GAA | |
| SCHEMBL294721 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1GAANPC1 | |
| SCHEMBL30136447 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1GAANPC1 | |
| SCHEMBL1704521 | 0.83 | ABL1 (0.62) | SYKALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL5690752 | 0.83 | SQOR (0.55) | SYKALDH1A1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111511-A2 | REVERSIBLY REACTIVE AFFINITY SELECTION MASS SPECTROMETRY AND USES THEREOF | CALICO LIFE SCIENCES LLC (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-3242875-B1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022036063-A2 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20020137974-A1 | Catalysis using phosphine oxide and sulfoxide compounds | DUPONT POLYMERS, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1235764-A1 | CATALYSIS USING PHOSPHINE OXIDE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6395916-B1 | AMINE, PHOSPHINE LIGANDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2002-05-28 | — | — | US | disclosed |
| WO-2002000574-A2 | CATALYSIS USING PHOSPHINE OXIDE AND SULFOXIDE COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| US-6307087-B1 | USE OF CATALYSTS COMPRISING THESE LIGANDS IN TRANSITION METAL-CATALYZED CARBON-HETEROATOM AND CARBON-CARBON BOND-FORMING REACTIONS. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-10-23 | — | — | US | disclosed |
| US-6291722-B1 | CONTACTING GRIGNARD REAGENT OF FORMULA R.SUP.7--MGX WITH AN ARYL COMPOUND OF THE FORMULA R.SUP.1--X IN THE PRESENCE OF A CATALYTIC AMOUNT OF COORDINATION COMPRISING TRASITION METAL COMPLEXED TO PHOSPHINE OXIDE TO PREPARE BISARYL COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| WO-2001040147-A1 | CATALYSIS USING PHOSPHINE OXIDE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6124462-A | PREPARING ARYLAMINE AND BIARYLS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | USP30, USP1, USP20 | SYK 3801/4885ALDH1A1 787/4885MAPK1 1265/4885 |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | SYK 2638/4885ALDH1A1 1172/4885MAPK1 3020/4885 |
| US-20020137974-A1 | Catalysis using phosphine oxide and sulfoxide compounds | TST, GSS, ARSA | SYK 1712/4885ALDH1A1 2774/4885MAPK1 1057/4885 |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | SYK 2615/4885ALDH1A1 1264/4885MAPK1 1601/4885 |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | SYK 2387/4885ALDH1A1 1220/4885MAPK1 1536/4885 |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | SYK 2615/4885ALDH1A1 1264/4885MAPK1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.